桂林三金：目前公司产品BC006单抗注射液项目，即将完成I期临床试验

Group 1 - The core point of the article is that Guilin Sanjin has confirmed the progress of its BC006 monoclonal antibody injection project, which is nearing the completion of Phase I clinical trials and is expected to enter Phase III soon [2] - The company stated that if a significant breakthrough is achieved, it will disclose the information in accordance with the requirements of the Shenzhen Stock Exchange [2]